The US Food and Drug Administration (FDA) has approved Lannett’s abbreviated new drug application (ANDA) of Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses.

Loxapine Capsules are therapeutically equivalent to Watson Pharmaceuticals’ Loxitane Capsules.

The company expects to start commercialising the product in the next few weeks.

Lannett president and CEO Arthur Bedrosian said they have now received five product approvals from the FDA over the last three months.

 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.